Antiviral Therapy Decreases Recurrence of Hepatitis B Virus‐related Hepatocellular Carcinoma after Curative Resection: A Meta‐analysis

Abstract

High DNA level is associated with posthepatectomy recurrence of HBV-related HCC. Nucleos(t)ide analog therapy improves the prognosis of HBV-related HCC after resection.

Long‐Term Outcome After Resection of Huge Hepatocellular Carcinoma ≥10 cm: Single‐Institution Experience with 471 Patients

“…More than 90 % of HBVpositive patients became HBV DNA-negative during postoperative follow-up due to vigorous antiviral treatment [12].…”

The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients

“…More than 90 % of HBV-positive patients became HBV DNA-negative during postoperative follow-up due to vigorous antiviral treatment. 16 The general principles of treatment for recurrent HCC lesions were applied to the study population, but patients having undergone salvage liver transplantation were excluded due to different survival outcomes. 17 Every locoregional treatment was performed including transarterial chemoembolization (TACE), radiofrequency ablation (RFA), percutaneous ethanol injection therapy (PEIT), external beam radiotherapy (EBRT), and surgical resection.…”

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

“…In a recent meta-analysis including 8,204 patients status-post curative resection of HCC, high viral load was significantly associated with increased risk of recurrence, poorer disease-free survival and overall survival of HBV-related HCC after surgical resection. However, NA therapy significantly decreased the recurrence risk (RR 0.69; 95%CI 0.59-0.80; P < 0.001) and improved both disease-free (RR 0.70; 95%CI 0.58-0.83; P < 0.001) and overall survival (RR 0.46; 95%CI 0.32-0.68; P < 0.001) in these patients [41] . Clearly, surgical and medical treatment of CHB improves mortality due to HCC and reduces its recurrence.…”